4CPS-166 Switching to alemtuzumab in patients with relapsing remitting multiple sclerosis

BACKGROUND: Alemtuzumab is a monoclonal antibody directed against the CD52 antigen on T- and B-lymphocytes indicated in adult patients with relapsing remitting multiple sclerosis (RRMS). PURPOSE: To assess safety, reason for switching, compliance with the protocol and with the criteria for use. MATE...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur J Hosp Pharm
Hlavní autoři: Arias, A, Blanc, R Menárguez, Torrón, A Martínez, Fernández, C Carriles, María, MC Rosado, Roces, L Velasco, García, I Zapico, Lozano-Blázquez, A
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Group 2018
Témata:
Section 4: Clinical pharmacy services
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535247/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.257
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky